Navigation Links
UCSD research reveals mechanism involved with type of fatal epilepsy

Researchers at University of California, San Diego (UCSD) have found that Lafora disease, an inherited form of epilepsy that results in death by the age of 30, can be caused by mutations in a gene that regulates the concentration of the protein laforin. These findings are reported in the current issue of Proceedings of the National Academy of Sciences (PNAS).

Lafora disease is characterized by normal development for the first decade of life, followed by an initial seizure in the second decade, progressively worsening seizures, early dementia, and death within 10 years of onset. Medications can ease the severity of initial symptoms, but there is no long-term treatment or cure for the disease.

A puzzling aspect of the disease is the accumulation of starch-/glycogen-like granules in most tissues of Lafora disease patients. Thus, researchers have long thought that a defect in glycogen metabolism is intimately linked to the disease. Recessive mutations in two genes have been shown to cause Lafora disease. The genes encode the proteins laforin and malin, but the molecular mechanism defining how loss of laforin or malin causes Lafora disease has remained unclear.

Jack E. Dixon, Ph.D., UCSD dean of scientific affairs and professor of pharmacology, and colleagues at UCSD investigated the role of malin in Lafora disease and found that malin physically interacts with laforin and regulates laforin's concentration by marking it for degradation. Their results show that approximately 40 percent of patients with Lafora disease have mutations in malin that render it unable to mark laforin for degradation. This increase in laforin may lead to Lafora disease through aberrant glycogen metabolism.

This work establishes a few testable models as to the molecular mechanism of the disease. Dixon and colleagues are currently designing experiments to test these models with the hope of gaining the necessary insights to develop potential therapies for Lafora disea
'"/>

Source:University of California - San Diego


Page: 1 2

Related biology news :

1. Columbia research lifts major hurdle to gene therapy for cancer
2. U of M researcher examines newly emerging deadly disease
3. NYU researchers simulate molecular biological clock
4. First atlas of key brain genes could speed research on cancer, neurological diseases
5. New research questions basic tenet of neuron function
6. Vital step in cellular migration described by UCSD medical researchers
7. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
8. UCSD researchers maintain stem cells without contaminated animal feeder layers
9. Why do insects stop breathing? To avoid damage from too much oxygen, say researchers
10. New protein discovered by Hebrew University researchers
11. First real-time view of developing neurons reveals surprises, say Stanford researchers
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: UCSD research reveals mechanism involved with type fatal epilepsy

(Date:5/11/2015)... -- Through a well-rounded UAS delegation representing private industry, government, and ... at AUVSI,s Unmanned 2015 conference last week in ... UAS industry met with over 200 hundred people from ... UAS ecosystem. "Our message is clear and ... Rich Knoll . "If you want to fly UAS, ...
(Date:5/10/2015)... Fingerprint Cards (FPC) has received an order for ... World Peace Industrial Group (WPI), part of WPG Holdings. WPI ... . Deliveries are planned to take place during Q3 2015 ... China . The order value of 235 ... 1 000 MSEK for 2015.   Jörgen Lantto, acting ...
(Date:5/7/2015)... Sweden , May 7, 2015 ... touch fingerprint sensors, FPC1022 and FPC1035, FPC,s smallest ... and FPC1035 are mainly considered for integration on ... size gives smartphone OEMs increased possibilities to integrate ... The decreased size also improves possibilities for module ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... the most common type of lung cancer are notoriously ... to the cellular pathways that regulate responses to cisplatin ... 26th in the journal Cell Reports . The ... to predict how these patients will respond to chemotherapy, ...
... Hole Oceanographic Institution (WHOI) researchers have partnered with ... developed at WHOI: the Imaging FlowCytobot, an automated ... that uses light to provide wireless transmission of ... time. WHOI biologists Robert Olson and Heidi ...
... University of Leeds and the Chinese Academy of Sciences have ... next generation energy storage systems. Finding more effective and ... deal with the problem of peak demand on electricity grids. ... solar generation is also a pressing problem. People use ...
Cached Biology News:New biomarker for common lung cancer predicts responses to chemotherapy 2WHOI scientists/engineers partner with companies to market revolutionary new instruments 2WHOI scientists/engineers partner with companies to market revolutionary new instruments 3WHOI scientists/engineers partner with companies to market revolutionary new instruments 4University of Leeds and Chinese Academy of Sciences join forces 2University of Leeds and Chinese Academy of Sciences join forces 3
(Date:6/1/2015)... , June 1, 2015  Fennec Pharmaceuticals, Inc. ... positive interim results from a poster presented today ... label randomised phase III trial of the efficacy ... patients receiving cisplatin (Cis) monotherapy for standard risk ... American Society of Clinical Oncology (ASCO) 2015 Annual ...
(Date:6/1/2015)... Minn. and SOUTH SAN FRANCISCO, ... Ventures, the venture arm of Baxter International Inc. (NYSE: ... Development, LLC ("VPD") today announced the formation of Vitesse ... initiated by Baxter Ventures to focus on the development ... immunology, hematology, and oncology. Following the spin-off of Baxter ...
(Date:6/1/2015)... June 1, 2015 Esperance Pharmaceuticals Inc. today ... lead candidate EP-100 in ovarian cancer patients resistant to ... seek and destroy cancer cells that overexpress luteinizing hormone-releasing ... over-expressed in a wide range of cancers. ... trial of EP-100 were presented at the 2015 ...
(Date:6/1/2015)... 29, 2015 Research and Markets ... of the "2015 Strategies in European ... their offering. This new 273-page ... diagnostic market, including emerging tests, technologies, instrumentation, ... of leading suppliers. Companies Mentioned: ...
Breaking Biology Technology:Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 2Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 5Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 3
... 30, 2011 Current Ceo Rudi Pauwels ... , New Ceo   Appointment Strengthens ... Of Its   First Product In 2013 ... diagnostic (MDx) systems designed to drive personalized medicine and ...
... Nov. 30, 2011  DiaTech Life Sciences has announced the ... use of the Microculture Kinetic (MiCK) assay for ... chemotherapy is most effective for cancer patients. DiaTech has ... developed a model to assist pharmaceutical companies in validating ...
... today that Lex Van der Ploeg, PhD, has joined ... Ploeg brings to Rhythm more than 25 years of ... therapeutic areas. "Lex has considerable experience with ... are targeting with our ghrelin and melanocortin 4 receptor ...
Cached Biology Technology:Biocartis Names Dr. Nayan Gregory Parekh As Chief Executive Officer 2Biocartis Names Dr. Nayan Gregory Parekh As Chief Executive Officer 3Biocartis Names Dr. Nayan Gregory Parekh As Chief Executive Officer 4DiaTech Life Sciences Announces Medical Advisory Board 2DiaTech Life Sciences Announces Medical Advisory Board 3Rhythm Names Lex Van der Ploeg Chief Scientific Officer 2
Request Info...
Bovine Serum Albumin Peroxidase Stabilizer Solution, 1 L...
SAIVI Alexa Fluor 680 injectable contrast agent *bovine serum albumin*...
... Lysate contains the cellular components necessary for ... elongation and termination factors) but has not ... is used primarily for the isolation of ... of endogenous globin mRNA. Untreated Lysate is ...
Biology Products: